Automate Your Wheel Strategy on ETNB
With Tiblio's Option Bot, you can configure your own wheel strategy including ETNB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ETNB
- Rev/Share 0.0001
- Book/Share 3.3046
- PB 4.4877
- Debt/Equity 0.0028
- CurrentRatio 15.1857
- ROIC -0.8267
- MktCap 2199276572.0
- FreeCF/Share -2.7818
- PFCF -5.0076
- PE -5.2006
- Debt/Assets 0.0024
- DivYield 0
- ROE -0.9448
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 3
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ETNB | H.C. Wainwright | -- | Buy | -- | $32 | Sept. 4, 2025 |
| Initiation | ETNB | Goldman | -- | Neutral | -- | $11 | March 14, 2025 |
| Initiation | ETNB | Citigroup | -- | Buy | -- | $25 | March 13, 2025 |
| Initiation | ETNB | Wolfe Research | -- | Outperform | -- | -- | Feb. 4, 2025 |
News
3 Potential Biotech Acquisition Targets
Published: September 19, 2025 by: Seeking Alpha
Sentiment: Positive
There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have good balance sheets. The article below discusses three promising names that have bright futures but also could attract interest from larger names in the industry.
Read More
89BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 89bio, Inc. - ETNB
Published: September 19, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of 89bio, Inc. (NasdaqGM: ETNB) to Roche Holding AG (OTC: RHHBY). Under the terms of the proposed transaction, shareholders of 89bio will receive $14.50 per share in cash at closing, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $6.00 per sh.
Read More
89bio, Inc. (ETNB) Presents At Cantor Global Healthcare Conference 2025 (Transcript)
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
89bio, Inc. (NASDAQ:ETNB ) Cantor Global Healthcare Conference 2025 September 4, 2025 11:30 AM EDT Company Participants Rohan Palekar - CEO & Director Conference Call Participants Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Presentation Steven Seedhouse MD & Biotechnology Analyst Well, welcome, everyone, and it's really a privilege for me to introduce our next participating company at the Cantor Global Healthcare Conference. First time Steve Seedhouse from the biotech team.
Read More
89bio, Inc. (ETNB) Presents At Citi's Biopharma Back To School Conference Transcript
Published: September 03, 2025 by: Seeking Alpha
Sentiment: Neutral
89bio, Inc. (NASDAQ:ETNB ) Citi's Biopharma Back to School Conference September 3, 2025 11:15 AM EDT Company Participants Rohan Palekar - CEO & Director Conference Call Participants Geoffrey Meacham - Citigroup Inc., Research Division Presentation Geoffrey Meacham Managing Director So welcome to the next session of the Citi Biopharma back-to-school event. So my name is Geoff Meacham.
Read More
89bio: Promising As Pegozafermin Nears Phase 3 Readout
Published: August 11, 2025 by: Seeking Alpha
Sentiment: Positive
Pegozafermin is ETNB's long-acting FGF21 analog. It's undergoing three Phase 3 trials. Two of those late-stage trials are for MASH (F2-F4), and the third is for severe hypertriglyceridemia. Also, ETNB's ENTRUST SHTG is fully enrolled, with potential topline data by 1Q 2026, which may enable a BLA filing shortly after that.
Read More
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year?
Published: March 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how 89BIO (ETNB) and Eton Pharmaceuticals, Inc. (ETON) have performed compared to their sector so far this year.
Read More
About 89bio, Inc. (ETNB)
- IPO Date 2019-11-11
- Website https://www.89bio.com
- Industry Biotechnology
- CEO Rohan Palekar
- Employees 93